CBLL NASDAQ
CeriBell, Inc.
1W: +0.0%
1M: -4.5%
3M: +19.7%
YTD: +11.2%
1Y: +104.9%
$23.69
+0.08 (+0.34%)
Weekly Expected Move ±4.8%
$21
$23
$24
$25
$26
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (43)
Bank of America Corp DE Purchases New Shares in CeriBell, Inc. $CBLL
BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL
Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL
Ceribell expects $114M-$117M 2026 revenue as CMS finalizes delirium NTAP up to $2,171 per patient
Here's What Key Metrics Tell Us About CeriBell, Inc. (CBLL) Q2 Earnings
CeriBell, Inc. (CBLL) Reports Q2 Loss, Tops Revenue Estimates
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates
Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System
CeriBell, Inc. (NASDAQ:CBLL) Receives $22.20 Consensus Target Price from Analysts
Is CeriBell, Inc. (CBLL) Among the Best Brain-Computer Interface Stocks to Buy?
Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates
CeriBell (CBLL) Q1 2026 Earnings Transcript
Ceribell Reports First Quarter 2026 Financial Results
Phibro Animal Health (PAHC) Q3 Earnings and Revenues Surpass Estimates
CeriBell, Inc. (NASDAQ:CBLL) Receives $23.20 Average PT from Brokerages
Green Thumb Industries Inc. (GTBIF) Moves 10.0% Higher: Will This Strength Last?
Xingjuan Chao Sells 39,000 Shares of CeriBell (NASDAQ:CBLL) Stock
Raymond Woo Sells 11,112 Shares of CeriBell (NASDAQ:CBLL) Stock
Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) PT at $24.67
Brokerages Set CeriBell, Inc. (NASDAQ:CBLL) Target Price at $24.67
CeriBell outlines $111M–$115M 2026 revenue target as new neuromonitoring products launch
CeriBell, Inc. (CBLL) Q4 2025 Earnings Call Transcript
CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates
CeriBell GAAP EPS of -$0.36 beats by $0.05, revenue of $24.8M beats by $0.85M
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
CeriBell, Inc. (NASDAQ:CBLL) Receives $24.67 Average Price Target from Analysts
CeriBell (NASDAQ:CBLL) Director Josef Parvizi Sells 25,000 Shares of Stock
CeriBell Maps 2026 Growth at JPMorgan MedTech, Eyes Delirium and Stroke EEG Expansion
CeriBell, Inc. (CBLL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution
Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 36,000 Shares of Stock
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
CeriBell, Inc. (NASDAQ:CBLL) Receives $25.17 Average Target Price from Brokerages
Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference